PATENT CLAIM ANALYSIS

Application Number: 16094172
Application Type: Utility
Filing Date: 2018-10
Publication Date: 2019-05
Patent Classification: ["424", "136100"]

Abstract:
The present invention provides a bispecific construct comprising a first binding domain specifically binding to CD33 and a second binding domain specifically binding to CD3 for use in a method for the treatment of myeloid leukemia, wherein the construct is administered for a maximal period of 14 days followed by a period of at least 14 days without administration of the construct. Moreover, the invention provides a method for the treatment of myeloid leukemia comprising the administration of a therapeutically efficient amount of such bispecific construct and the use of such bispecific construct for the preparation of a pharmaceutical composition for the treatment of myeloid leukemia.

Claim (Index 10):
The bispecific construct for the use according to any one of  claims 1  to  9 , wherein the bispecific construct is a bispecific antibody construct.

Metadata:
- Claim Count in Document: 44.0
- Percentile: 97.0
- Lexical Diversity: 2.2449
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15934770', '12095951', '15604153', '14937494', '12101785']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7001426486487963
- 35 USC 102 Novelty (BERT): 0.5091445789214792
- Combined Prediction Score: 0.6810428416760645
- Mean Citation Score: 232.315448
- Max Citation Score: 239.4421
- Similarity Product: 164.1388501829624

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test